[Relationship between genetic polymorphism of NAT2 and susceptibility to urinary bladder cancer].
OBJECTIVE
To study the relationship between genetic polymorphism of NAT2 and susceptibility to bladder cancer.


METHODS
NAT2 genotypes were determined by PCR-RFLP method in 69 patients with bladder transitional cell carcinoma and 88 healthy controls.


RESULTS
The frequency of NAT2 slow genotypes was 26.1% (18/69) in patients compared with 14.8% (13/88) in controls (P < 0.05). Bladder cancer risk in patients with NAT2 slow genotypes was 2 fold as high as that in patients with NAT2 rapid genotypes. When NAT2 rapid genotypes/non-smoker were used as reference, bladder cancer risk increased to 5.8-fold (P < 0.05). Among the smokers with PY higher than 10, the patients showed a higher frequency of NAT2 slow genotype than controls (P < 0.05). It was also shown that the patients with slow NAT2 genotypes were more likely to have high grade tumor (P < 0.05) and advanced stage tumor (P < 0.01).


CONCLUSIONS
The results suggest that NAT2 genetic polymorphism is associated with bladder cancer susceptibility. People with NAT2 slow genotype have higher bladder cancer risk.
Department of Urology, Beijing Friendship Hospital, Capital University of Medical Sciences, Beijing 100050, China. haogangyue@hotmail.com
Gang-yue
GY
Hao
Wei-dong
WD
Zhang
Yong-he
YH
Chen
Dao-xin
DX
Zhang
Yu-hai
YH
Zhang
D001191:Arylamine N-Acetyltransferase / Q000235:genetics*; D002295:Carcinoma, Transitional Cell / Q000201:enzymology / Q000235:genetics* / Q000473:pathology; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016133:Polymerase Chain Reaction; D012150:Polymorphism, Restriction Fragment Length; D012907:Smoking; D001749:Urinary Bladder Neoplasms / Q000201:enzymology / Q000235:genetics* / Q000473:pathology
D001191:Arylamine N-Acetyltransferase; C478900:NAT2 protein, human